Tags

Type your tag names separated by a space and hit enter

Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats.
J Hypertens. 1995 Jun; 13(6):647-52.JH

Abstract

OBJECTIVE

The effect of the combined ETA/ETB endothelin receptor antagonist bosentan was evaluated in 4-week-old spontaneously hypertensive rats (SHR) and control Wistar-Kyoto (WKY) rats, which were treated for 10 weeks, to determine whether endothelins were involved in the development of hypertension or cardiovascular remodeling in young SHR.

METHODS

Four-week-old SHR and WKY rats received bosentan 100 mg/kg per day mixed with their food. Blood pressure was measured by the tail-cuff method every 2 weeks. At 14 weeks of age the coronary, renal, mesenteric and femoral small arteries were examined on a wire myograph.

RESULTS

The blood pressure both of SHR and of WKY rats was identical in bosentan-treated and untreated rats throughout the study. The media width, lumen diameter, media width:lumen diameter ratio and media cross-sectional area of small arteries of the four vascular beds examined were similar in bosentan-treated and untreated SHR, as were the wet weights of aorta segments and the mesenteric vascular bed.

CONCLUSION

Endothelins are not involved in the development of hypertension or vascular hypertrophy and remodelling in young SHR.

Authors+Show Affiliations

Clinical Research Institute of Montreal, University of Montreal, Quebec, Canada.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7594422

Citation

Li, J S., and E L. Schiffrin. "Chronic Endothelin Receptor Antagonist Treatment of Young Spontaneously Hypertensive Rats." Journal of Hypertension, vol. 13, no. 6, 1995, pp. 647-52.
Li JS, Schiffrin EL. Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. J Hypertens. 1995;13(6):647-52.
Li, J. S., & Schiffrin, E. L. (1995). Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. Journal of Hypertension, 13(6), 647-52.
Li JS, Schiffrin EL. Chronic Endothelin Receptor Antagonist Treatment of Young Spontaneously Hypertensive Rats. J Hypertens. 1995;13(6):647-52. PubMed PMID: 7594422.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic endothelin receptor antagonist treatment of young spontaneously hypertensive rats. AU - Li,J S, AU - Schiffrin,E L, PY - 1995/6/1/pubmed PY - 1995/6/1/medline PY - 1995/6/1/entrez SP - 647 EP - 52 JF - Journal of hypertension JO - J Hypertens VL - 13 IS - 6 N2 - OBJECTIVE: The effect of the combined ETA/ETB endothelin receptor antagonist bosentan was evaluated in 4-week-old spontaneously hypertensive rats (SHR) and control Wistar-Kyoto (WKY) rats, which were treated for 10 weeks, to determine whether endothelins were involved in the development of hypertension or cardiovascular remodeling in young SHR. METHODS: Four-week-old SHR and WKY rats received bosentan 100 mg/kg per day mixed with their food. Blood pressure was measured by the tail-cuff method every 2 weeks. At 14 weeks of age the coronary, renal, mesenteric and femoral small arteries were examined on a wire myograph. RESULTS: The blood pressure both of SHR and of WKY rats was identical in bosentan-treated and untreated rats throughout the study. The media width, lumen diameter, media width:lumen diameter ratio and media cross-sectional area of small arteries of the four vascular beds examined were similar in bosentan-treated and untreated SHR, as were the wet weights of aorta segments and the mesenteric vascular bed. CONCLUSION: Endothelins are not involved in the development of hypertension or vascular hypertrophy and remodelling in young SHR. SN - 0263-6352 UR - https://www.unboundmedicine.com/medline/citation/7594422/Chronic_endothelin_receptor_antagonist_treatment_of_young_spontaneously_hypertensive_rats_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=7594422.ui DB - PRIME DP - Unbound Medicine ER -